Abstract
Pulmonary arterial hypertension (PAH) is a pathophysiological condition characterized by increased pulmonary vascular resistance (PVR), initially due to abnormal pulmonary vasoconstriction in response to endothelial injury. Recent studies confirmed the key role of endothelin (ET)-1 in the vasoconstriction and remodeling of pulmonary microcirculation during PAH. In responders patients, classical treatments for PAH are prostanoids, phosphodiesterase (PDE)-5 inhibitors and endothelin receptor antagonists (ERAs), which target prostaglandin I2, nitric oxide and endothelin pathways, respectively. Randomised, placebo-controlled trials have shown that ERAs improves haemodynamic parameters of the pulmonary circulation, functional capacity and clinical outcome in patients affected by PAH. Here, we will review the definition, classification and pathophysiology of PH. Furthermore, we will provide an up-to-date overview of currently recommended diagnostic and therapeutic work-up in PAH.
Keywords: Antagonists of endothelin receptor, PDE-5 inhibitors, prostanoids, pulmonary hypertension.
Current Drug Targets
Title:Novel Strategies in the Treatment of Pulmonary Arterial Hypertension
Volume: 17 Issue: 7
Author(s): Rosalinda Madonna and Nino Cocco
Affiliation:
Keywords: Antagonists of endothelin receptor, PDE-5 inhibitors, prostanoids, pulmonary hypertension.
Abstract: Pulmonary arterial hypertension (PAH) is a pathophysiological condition characterized by increased pulmonary vascular resistance (PVR), initially due to abnormal pulmonary vasoconstriction in response to endothelial injury. Recent studies confirmed the key role of endothelin (ET)-1 in the vasoconstriction and remodeling of pulmonary microcirculation during PAH. In responders patients, classical treatments for PAH are prostanoids, phosphodiesterase (PDE)-5 inhibitors and endothelin receptor antagonists (ERAs), which target prostaglandin I2, nitric oxide and endothelin pathways, respectively. Randomised, placebo-controlled trials have shown that ERAs improves haemodynamic parameters of the pulmonary circulation, functional capacity and clinical outcome in patients affected by PAH. Here, we will review the definition, classification and pathophysiology of PH. Furthermore, we will provide an up-to-date overview of currently recommended diagnostic and therapeutic work-up in PAH.
Export Options
About this article
Cite this article as:
Madonna Rosalinda and Cocco Nino, Novel Strategies in the Treatment of Pulmonary Arterial Hypertension, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450116666150722140424
DOI https://dx.doi.org/10.2174/1389450116666150722140424 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resilience to Alzheimer's Disease: The Role of Physical Activity
Current Alzheimer Research Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Calcium Channel Blockers in Restoration of Endothelial Function: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Phytochemical and Pharmacological Investigation of Cassia Siamea Lamk: An Insight
The Natural Products Journal Management of Measurable Variable Cardiovascular Disease' Risk Factors
Current Cardiology Reviews Gemini Analogs of Vitamin D
Current Topics in Medicinal Chemistry The Use of Human Albumin for the Treatment of Ascites in Patients with Liver Cirrhosis: Item of Safety, Facts, Controversies and Perspectives
Current Drug Safety Enkephalin Degrading Enzymes: Metalloproteases with High Potential for Drug Development
Current Pharmaceutical Design Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Imidazoline Receptor Agonists in Obesity-Related Hypertension: Therapeutic Targeting of the Sympathetic Nervous System
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets A Novel Design of Combining the Angiotensin Converting Enzyme (ACE) Inhibitor Captopril with the Angiotensin Receptor Blocker (ARB) Losartan Using Homo Coupling via PEG Diacid Linker
Recent Patents on Cardiovascular Drug Discovery Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection
Current HIV Research The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics
Current Pharmaceutical Design Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets Role of AGEs in Diabetic Nephropathy
Current Pharmaceutical Design Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Hypertension in Patients with Severe Aortic Stenosis: Emphasis on Antihypertensive Treatment and the Risk of Syncope
Current Hypertension Reviews Blood Pressure and the Risk of Dementia: A Dose-Response Meta-Analysis of Prospective Studies
Current Neurovascular Research